Search | Clinical Trials Finder

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more

Conditions: Middle Aged
Interventions: MASTERY, Attentional Control; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 64 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: Occupational and Physical Therapy; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Myeloid Leukemia
Interventions: modified Geriatric Assessment (mGA); Behavioral
Lead sponsor: Carevive Systems, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Geriatric Assessment, Frail Elderly, Skilled Nursing Facilities, Patient-centered Care
Interventions: Deprescribing intervention; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more

Conditions: Cystic Fibrosis
Interventions: TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Body Weight Changes
Interventions: Videos, Action Plans, Discussion Boards, Health behavior tracking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Auburn, Nebraska

Conditions: Generalized Myasthenia Gravis
Interventions: Iptacopan, Matching Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fullerton, California • Sacramento, California + 10 more

Conditions: Measles, Mumps, Rubella, Varicella (Chickenpox), Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions: MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 1,860 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 38
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Huntington Park, California + 32 more

Conditions: Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions: AZD3293, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more

Conditions: Dravet Syndrome
Interventions: Clobazam; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Orlando, Florida + 4 more

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Alzheimer's Disease (AD)
Interventions: ABBV-916, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 32
States / cities: Tucson, Arizona • Irvine, California • San Diego, California + 23 more

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Autism Spectrum Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Anaheim, California • Imperial, California • Orange, California + 28 more

Conditions: Major Depressive Diorder, Early Life Trauma
Interventions: Lumateperone 42 mg, Placebo; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Austin, Texas

Conditions: SARS-CoV-2
Interventions: Biological: mRNA-1273, Placebo, mRNA-1273.351; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Savannah, Georgia • Newton, Kansas • Kansas City, Missouri + 5 more

Conditions: Effects of Chemotherapy, Aging, Frailty
Interventions: Geriatric Assessments and Frailty Indices; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Influenza, Human
Interventions: D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 470 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Irvine, California

Conditions: Bladder Cancer
Interventions: Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery), Geriatric Service/ Discharge Planning, Questionnaires; Other
Lead sponsor: University of Chicago; Other
Eligibility: 65 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Text Messaging to Increase Activity in Midlife

The CARE Program: CAncer REhabilitation Pilot Study for Older Adults

Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia

Drug Reduction in Older Patients: The DROP Trial

Phase 3/Safety & Efficacy of Esomeprazole in Infants

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Weight Maintenance Through Physical Activity and Social Support in Rural Middle-Aged Women

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Aging and Frailty Study

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy